MedPath

Ohio State University Comprehensive Cancer Center

πŸ‡ΊπŸ‡ΈUnited States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.cancer.osu.edu

Clinical Trials

334

Active:36
Completed:196

Trial Phases

6 Phases

Early Phase 1:10
Phase 1:47
Phase 2:61
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (293 trials with phase data)β€’ Click on a phase to view related trials

Not Applicable
172 (58.7%)
Phase 2
61 (20.8%)
Phase 1
47 (16.0%)
Early Phase 1
10 (3.4%)
Phase 4
2 (0.7%)
Phase 3
1 (0.3%)

Strategies for Optimizing a Mailed FIT Program in Appalachia

Not Applicable
Not yet recruiting
Conditions
Colonic Neoplasms
First Posted Date
2025-09-15
Last Posted Date
2025-09-19
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
500
Registration Number
NCT07173985
Locations
πŸ‡ΊπŸ‡Έ

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Not Applicable
Not yet recruiting
Conditions
Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Recurrent Acute Lymphoblastic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive
Recurrent Indolent Non-Hodgkin Lymphoma
Recurrent Lymphoblastic Lymphoma
Recurrent Non-Hodgkin Lymphoma
Recurrent Transformed Chronic Lymphocytic Leukemia
Refractory Acute Lymphoblastic Leukemia
Refractory Chronic Lymphocytic Leukemia
Interventions
Biological: Autologous Anti-CD19/CD20/CD22 CAR T-cells
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
Procedure: Pheresis
Procedure: Positron Emission Tomography
First Posted Date
2025-09-10
Last Posted Date
2025-09-10
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
24
Registration Number
NCT07166419
Locations
πŸ‡ΊπŸ‡Έ

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

Not Applicable
Not yet recruiting
Conditions
Advanced Ovarian Carcinoma
Recurrent Ovarian Carcinoma
Stage II Ovarian Cancer AJCC v8
Stage III Ovarian Cancer AJCC v8
Stage IV Ovarian Cancer AJCC v8
Interventions
Procedure: Biospecimen Collection
Dietary Supplement: Probiotic
Drug: Placebo Administration
Other: Questionnaire Administration
First Posted Date
2025-08-28
Last Posted Date
2025-08-28
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
161
Registration Number
NCT07144826
Locations
πŸ‡ΊπŸ‡Έ

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer

Not Applicable
Not yet recruiting
Conditions
Localized Pancreatic Ductal Adenocarcinoma
Stage 0 Pancreatic Cancer AJCC v8
Stage I Pancreatic Cancer AJCC v8
Stage IIA Pancreatic Cancer AJCC v8
First Posted Date
2025-08-15
Last Posted Date
2025-08-15
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
25
Registration Number
NCT07124611
Locations
πŸ‡ΊπŸ‡Έ

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Studying Flavors and Cooling Agents in Oral Nicotine Pouches to Understand User Preferences

Not Applicable
Recruiting
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Procedure: Carbon Monoxide Measurement
Other: Questionnaire Administration
Drug: Smoke usual brand cigarette
First Posted Date
2025-08-08
Last Posted Date
2025-09-15
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
30
Registration Number
NCT07111234
Locations
πŸ‡ΊπŸ‡Έ

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 67
  • Next

News

TAE Life Sciences and Ohio State University Partner to Advance Boron Neutron Capture Therapy for Cancer Treatment

TAE Life Sciences and Ohio State University have formed the first U.S.-based academic-industry alliance focused on developing novel boron-based drug compounds for Boron Neutron Capture Therapy (BNCT).

ACCC Fall 2024: Innovations in Clinical Trial Access, Patient Care, and Treatment Authorization

The Ohio State University Cancer Center's automated informatics program has achieved a 21.9% increase in biosimilar utilization while streamlining prior authorization processes, earning an Innovator Award at ACCC 2024.

First-in-Human Trial Launched for Novel DHODH Inhibitor HOSU-53 in Solid Tumors and Lymphomas

A Phase I/II clinical trial is set to begin at Ohio State University, evaluating the novel DHODH inhibitor HOSU-53 in patients with advanced solid tumors and Non-Hodgkin's lymphoma.

Nanopharmaceutics Completes Enrollment in Phase 2 Neuroendocrine Tumor Study Combining Triapine with Lutetium Lu 177 Dotatate

Nanopharmaceutics has completed patient enrollment in a 94-patient Phase 2 randomized controlled trial evaluating Triapine plus lutetium Lu 177 dotatate versus standard therapy alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.